Trials

• Soligenix's HyBryte for cutaneous T-cell lymphoma (CTCL) has a second Phase 3 trial underway with enrollment of approximately 80 subjects, interim analysis in Q2 2026, and top-line results in H2 2026. • Previous Phase 3 trials showed statistical significance in primary endpoints across multiple cycles, following FDA NDA submission and RTF letter. • The program targets unmet needs in rare dermatological cancers with ongoing FDA discussions for development path.

Exclusive: Justice Jim Henry published data from his own court revealing recent cases took more than a year to reach committalGet our breaking news email, free app or daily news podcastA Queensland supreme court judge says serious criminal cases are taking “excruciatingly longer” to finalise due to “glacial” delays in the state’s magistrates court, where some matters are spending several years in procedural limbo.Justice Jim Henry, who is based at the supreme court in Cairns, published data from his own court revealing that of 31 recent criminal cases he finalised between November and February, on average each case took more than a year (370 days) in the lower courts before a committal. Continue reading...

• HHS through the National Cancer Institute announced a $200 million public-private partnership to fund clinical trials for cancer vaccines targeting high-risk recurrence patients. • The initiative supports mRNA and other vaccine types, aiming to accelerate development with private sector involvement including venture capital. • 'Nothing of this scale has been attempted in cancer vaccines before,' said Stacey Adam, VP of science partnerships for the Foundation for the National Institutes of Health.